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ToxicityPurpose: The HERBERT study was a dose-finding feasibility study of a high-dose rate endorectal
brachytherapy (HDREBT) boost after external beam radiotherapy (EBRT) in elderly patients with rectal
cancer who were unfit for surgery. This analysis evaluates the association of patient, tumor and dosimet-
ric parameters with tumor response and toxicity after HDREBT in definitive radiotherapy for rectal
cancer.
Patients and methods: The HERBERT study included 38 inoperable patients with T2-3N0-1 rectal cancer.
Thirteen fractions of 3 Gy EBRT were followed by three weekly HDREBT applications of 5–8 Gy per frac-
tion. Clinical and dosimetric parameters were tested for correlation with clinical complete response
(cCR), sustained partial/complete response (SR), patient reported bowel symptoms, physician reported
acute and late proctitis (CTCAE v3) and endoscopically scored toxicity.
Results: Thirty-five patients completed treatment and were included in the current analyses. Twenty of
33 evaluable patients achieved a cCR, the median duration of a sustained response was 32 months. Tumor
volume at diagnosis showed a strong association with clinical complete response (OR 1.15; p = 0.005). No
dose–response correlation was observed in this cohort. Prescribed dose to the brachytherapy CTV (D90)
correlated with acute and late physician reported proctitis while CTV volume, CTV width and high dose
regions in the CTV (D1cc/D2cc) were associated with endoscopic toxicity at the tumor site.
Conclusion: Tumor volume is the most important predictive factor for tumor response and a higher dose
to the brachytherapy CTV increases the risk of severe clinically and endoscopically observed proctitis
after definitive radiotherapy in elderly patients with rectal cancer.
 2019 Elsevier B.V. All rights reserved. Radiotherapy and Oncology 133 (2019) 176–182Over the last decades, radiotherapy for rectal cancer has
developed substantially. While total mesorectal excision (TME)
with or without neo-adjuvant (chemo)radiotherapy remains the
gold standard, risk of surgical morbidity and mortality and the
possibility of a clinical or pathologic complete response after
neo-adjuvant treatment have led to increasing interest in organ
preservation strategies [1,2]. Especially in elderly fragile patients
with multiple comorbidities, surgical risks might outweigh the
possible improved long-term oncological outcome [3]. With rising
awareness for organ preservation, it is important to understand
which factors are associated with a complete response. Previous
studies describe a radiotherapy dose–effect relationship for rectal
cancer [4,5]. A possible option for dose escalation is the use ofhigh-dose rate endorectal brachytherapy (HDREBT), which allows
for high doses to the tumor with sparing of the surrounding organs.
The HERBERT study was a dose escalation study, performed to
evaluate the feasibility of a HDREBT boost after external beam
radiotherapy (EBRT) in elderly patients with T2-3N0-2 rectal
cancer who were unfit for standard TME surgery. The primary end-
point was the maximum tolerated brachytherapy boost dose after
13x3Gy external beam radiotherapy. This was set at 3  7 Gy after
three patients in the dose level with 8 Gy per fraction experienced
acute grade 3 proctitis [6].
Of the 38 patients included in the study, 35 completed
brachytherapy treatment and 33 had endoscopic follow-up and
were therefore evaluable for response analyses. Overall response
was high (90% complete or partial response) and 60% achieved a
clinical complete response. Severe toxicity was however not
uncommon and occurred in approximately one third of patients
[6].
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cer. Treatment schedules between these studies vary widely and
no consensus exists on dose prescription, fractionation or con-
straints for organs at risk [7]. Therefore it is of importance to better
understand which patient, tumor and treatment characteristics
have predictive value for tumor response and toxicity. This will
aid in selection of patients who are most likely to benefit from a
HDREBT boost. The aim of the current analyses is to evaluate
patient, tumor and treatment parameters in relation to tumor
response and toxicity in the HERBERT study.
Materials and methods
A dose finding feasibility study was performed from 2007 to
2013 in elderly or medically inoperable patients with cT2-3N0-2
rectal cancer. Patients received 13 fractions of 3 Gy EBRT followed
by three weekly HDREBT applications of 5, 6, 7 or 8 Gy per fraction
six weeks after EBRT. Details of the study design and methods have
been described previously [6,8].
Endorectal brachytherapy
For HDREBT a flexible applicator with a central canal and 8
peripheral catheters (Intracavitary Mold Applicator, ELEKTA, Vee-
nendaal, The Netherlands) was used in combination with an inflat-
able semi-circular balloon to fixate the applicator and push away
the normal rectal wall. HDREBT was performed with an Iridium-
192 source using a microSelectron HDR after loader (Elekta, Vee-
nendaal, the Netherlands). Treatment planning was performed
with Oncentra Brachy (Elekta, Veenendaal, the Netherlands) on a
planning-CT with applicator in situ acquired prior to the first
brachytherapy application. The aim of treatment planning was
complete coverage of the clinical target volume (CTV) by the
100% isodose with no hotspots in the surrounding organs. The
CTV was defined as the area suspicious for residual tumor and/or
scarring at time of brachytherapy. Delineation was performed on
the planning-CT by two observers using information of the diag-
nostic MRI, endoluminal clips at the proximal and distal border
of the tumor, and rectoscopy images with a clinical drawing
acquired prior to EBRT and during the first brachytherapy session.
In case of discrepancy between observers, consensus was sought
for the definitive CTV [6,9]. The 100% isodose was restricted to
2 cm from the applicator surface and during the course of the studyC
C
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Fig. 1. Example of brachytherapy treatment planning in a patient with a small tumor (
tumor, dose to the HDREBT CTV D2cc is increased. As a result, tumor volume and the Can additional constraint of 400% at the applicator surface was
added. The brachytherapy treatment plan of the first fraction was
used for the 2nd and 3rd fraction. Orthogonal x-rays, visualizing
endoluminal clips that were placed at the borders of the tumor,
allowed for position verification at time of each brachytherapy
fraction [10].
Tumor characteristics and DVH parameters
The tumor was delineated on the diagnostic MRI to assess the
baseline tumor volume. The HDREBT CTV, contralateral rectal wall
and anal canal were delineated on the HDREBT planning-CT. The
contralateral rectal wall was defined as the rectal wall, excluding
lumen and CTV, extending 3 cm proximal and distal to the CTV.
Fig. 1 shows two examples of contoured structures and HDREBT
planning. Dose–volume histogram (DVH) parameters were col-
lected from the initial planning-CT for CTV coverage: CTV D98
and CTV D90 and for high dose regions in the CTV; D1cc, D2cc
and D5cc and dose in the contralateral wall and the anal canal:
D2cc and D5cc. A point dose on the lumen side of the contralateral
wall directly opposing the center of the CTV was also collected. All
doses are described as physical dose per HDREBT fraction (Gy/#).
In addition, the isodose volumes, including applicator and lumen,
corresponding to a cumulative total 2 Gy equivalent total dose
(EQD2) of 60 Gy and 75 Gy were acquired using an a/b = 3 for late
toxicity endpoints and a/b = 10 for tumor control [4] and acute
toxicity.
Endpoints
Clinical tumor response evaluation was based on digital rectal
examination and endoscopy and was performed prior to
brachytherapy, at two and six months and yearly after brachyther-
apy. Maximum response was determined, including information of
multiple endoscopic evaluations if needed, and was categorized as
clinical complete response (cCR), partial response (PR; >30%
decrease of tumor bulk on endoscopy images), stable disease
(SD; 30% decrease or 20% increase) or progressive disease (PD
>20% increase in tumor bulk on endoscopy images). Complete
responders (cCR) were compared to non-complete responders
(no cCR). Sustained response was defined as complete or partial
response with time calculated from start of EBRT to progression.
Patients were censored at time of death or loss of follow-up.Dose level 8 Gy
HDREBT CTV D98:     4.09 Gy  
HDREBT CTV D90:     5.08 Gy  








A) and with a larger tumor (B). To achieve acceptable tumor coverage in the larger
TV D2cc showed are correlated.
Table 1






Baseline tumor measurements Median Range
Tumor volume (cc)* 11.3 2.1–39.8
Tumor thickness (mm)* 16 5–34
Tumor length (cm)y 4.0 1.5–6.0
Distance from anal verge (cm)y 6.0 2.0–15.0
Tumor circumference (%)y 40 15–90
HDREBT CTV characteristics
CTV volume (cc) 7.2 2.0–25.0
CTV max thickness (mm) 10 4–30
CTV length (cm) 3.1 1.8–6.4
CTV width (cm) 3.8 1.0–7.9
CTV circumference % 30 20–80
HDREBT DVH parameters per fraction
CTV D98 (Gy/#) 6.0 1.2–8.8
CTV D90 (Gy/#) 7.2 1.8–9.8
CTV D1cc (Gy/#) 14.9 7.9–28.4
CTV D2cc (Gy/#) 12.9 5.3–22.5
CTV D5cc (Gy/#) 9.2 3.6–15.0
Contralateral rectal wall
Contralateral wall D2cc (Gy/#) 8.1 3.7–14.2
Contralateral wall D5cc (Gy/#) 5.9 2.6–11.6
Point dose contralateral wall (Gy/#) 5.0 1.7–18.7
Anal canal
Anal canal D2cc (Gy/#) 1.2 0.0–4.4
Anal canal D5cc (Gy/#) 1.0 0.0–3.2
Volume cumulative dose§
Volume EQD2 60 Gy a/b = 3 (cc) 102.9 26.2–203.1
Volume EQD2 60 Gy a/b = 10 (cc) 61.9 16.9–123.6
Volume EQD2 75 Gy a/b = 3 (cc) 50.0 13.7–104.4
Volume EQD2 75 Gy a/b = 10 (cc) 33.0 9.0–70.3
Abbreviations: HDREBT, High dose rate endorectal brachytherapy. EQD2, equivalent
dose in 2 Gy fractions. Gy/#, Gy per brachytherapy fraction.
* Based on delineation on diagnostic MRI.
y Based on diagnostic endoscopy and MRI.
 Based on HDREBT planning-CT.
§ Volume derived from isodose lines (including applicator) corresponding to a
cumulative dose of 60 and 75 Gy.
178 Predictive factors for response and toxicity after rectal brachytherapyEvaluation of clinical and endoscopic toxicity has been previ-
ously reported [9]. In summary, toxicity was assessed via three
methods: (1) Patient reported bowel symptoms (PROM), assessed
by questionnaires acquired from start of HDREBT to 2 months after
HDREBT. Symptoms concerning pain with stools, painful abdomi-
nal cramps/urge, tenesmus, mucus discharge, fecal incontinence
and bowel function in general were scaled, (2) Clinical toxicity
(CTCAE v3): acute and late clinical proctitis and late grade 2 rec-
tal bleeding and incontinence. (3) Endoscopic evaluation: endo-
scopically scored toxicity at the tumor site was categorized as 0.
erythema or scarring, 1. superficial ulcer and 2. (very) deep ulcer,
and toxicity at the contralateral wall as 0. normal mucosa; 1. mild
erythema; 2. diffuse erythema and punctate hemorrhage; 3. frank
hemorrhage and 4. ulceration [11]. Patients with SD or PD were
excluded for late toxicity and evaluation of endoscopically scored
toxicity at the tumor site.
Statistical analyses
Statistical analyses were performed with SPSS version 23.0
(IBM, Armonk, NY). Correlation of factors was assessed using
Spearman’s correlation. Further analyses for association were per-
formed with the Armitage test for trend for ordinal variables and
the Kruskal–Wallis H and Mann–Whitney U test for continuous
variables. Logistic regression and cox-regression were used for
uni- and multivariable analyses. Due to small sample size, multi-
variable analyses were only performed for binary outcome mea-
sures with a maximum of 2 variables. A p-value < 0.01 was
considered significant to correct for multiple testing.
Results
Thirty-five of 38 patients included in the study completed treat-
ment and were included in the current analyses. All 35 patients
were available for evaluation of acute toxicity, 26 for late toxicity
and 33 for response evaluation. Baseline patient characteristics
have been previously reported [6]. Patients were mainly elderly
with a median age of 83 years and most patients had severe
comorbidity, with 80% classified as American Society of Anesthesi-
ology III to IV and 69% anticoagulant use. Twenty patients had a
cT2 tumor and fifteen a cT3 tumor. Of these fifteen, five had a
tumor with >5 mm fat infiltration (cT3c/d). MRI showed positive
nodes in 11 patients; N1 in 9 patients and N2 in 2 patients. Base-
line tumor characteristics and brachytherapy dose–volume his-
togram (DVH) parameters are listed in Table 1.
Clinical tumor response
After full treatment, clinical complete response was achieved in
20 of 33 evaluable patients. Seven of these patients already had a
cCR after EBRT alone. A sustained partial or complete response
(SR) was seen in 61.8% at one year, 54.7% at 2 years and 46.5% at
three years, with a median SR of 32 months. Table 2 shows the
results of the univariable analyses for cCR and for SR. Volume at
baseline was the only significant predictive factor for clinical com-
plete response; OR 1.15 (cc) p = 0.005. Median volume of patients
with a complete response was 10.8 cc vs. 27.3 cc in patients with-
out cCR (see Fig. 2A). Clinical nodal stage, response to EBRT, tumor
thickness at baseline and HDREBT CTV circumference all showed a
trend for association with cCR. In patients with positive lymph
nodes, complete tumor response rate was 36% compared to 73%
in cN0 patients (p = 0.05). Thirteen of twenty-one patients with a
partial response after EBRT achieved a cCR after HDREBT, while
none of five patients with stable disease achieved a cCR
(p = 0.01). For sustained response a trend was observed for tumorvolume, circumferential involvement and thickness at baseline
and for HDREBT CTV volume, length and circumferential involve-
ment (see Table 2). The effect of tumor volume at time of diagnosis
and at time of brachytherapy on complete and sustained response
is illustrated in Fig. 2. Patients with a baseline tumor volume <20 cc
had a 2 year sustained response rate of 74% compared to only 25%
for patients with baseline tumor volume >20 cc (p = 0.007).
No dose–response correlation was observed for HDREBT CTV
dose coverage (D98/D90). After correction for CTV volume in mul-
tivariable analyses still no association could be established. In uni-
variable analyses HDREBT CTV high dose regions (D1cc/D2cc)
showed a negative association with cCR and SR. CTV D2cc was
however correlated to CTV volume (q = 0.63; p < 0.001), illustrated
in Fig. 1) and after correction for CTV volume in multivariable anal-
yses this association was no longer detected.
Toxicity
Clinically relevant correlations between patient, tumor and
DVH parameters with toxicity endpoints are shown in Table 3. Full
analyses are available online in Web appendix A.
Acute toxicity
For patient reported bowel symptoms, a dose–response associ-
ation was found for all DVH parameters of the HDREBT CTV, with
Table 2
Univariable analyses for clinical complete response and local control.
Complete response Sustained response (CR/PR)
OR (95% CI) p HR (95% CI) p
Baseline n = 33 n = 33
cT-stage (cT3 vs. cT2) 1.75 (0.43–7.17) 0.44 1.32 (0.50–3.53) 0.58
cN-stage (N1-2 vs. N0) 4.67 (0.99–21.9) 0.05 2.15 (0.80–5.79) 0.13
Volume at baseline (cc) 1.15 (1.04–1.27) 0.005 1.05 (1.01–1.09) 0.02
Circumference at baseline (per 10%) 1.49 (0.99–2.26) 0.06 1.33 (1.04–1.68) 0.02
Thickness at baseline (mm) 1.16 (1.02–1.33) 0.02 1.08 (1.01–1.16) 0.03
Length at baseline (cm) 1.23 (0.72–2.10) 0.45 1.06 (0.75–1.51) 0.73
Distance to anal verge (cm) 0.99 (0.81–1.21) 0.91 0.98 (0.85–1.13) 0.78
HDREBT n = 26* n = 33
CTV volume (cc) 1.29 (0.98–1.69) 0.07 1.11 (1.01–1.21) 0.03
CTV circumference (per 10%) 2.21 (1.09–4.47) 0.03 1.36 (1.04–1.78) 0.03
CTV thickness (mm) 1.23 (0.96–1.56) 0.10 1.05 (0.96–1.15) 0.31
CTV length (cm) 1.64 (0.57–4.73) 0.36 1.64 (1.02–2.63) 0.04
CTV width (cm) 1.59 (0.76–3.34) 0.22 1.34 (0.96–1.87) 0.08
CTV D98 (Gy) 1.02 (0.62–1.69) 0.93 1.22 (0.82–1.80) 0.33
CTV D90 (Gy) 0.98 (0.62–1.55) 0.93 1.20 (0.84–1.73) 0.32
CTV D1cc (Gy) 1.16 (0.93–1.43) 0.19 1.13 (1.02–1.26) 0.03
CTV D2cc (Gy) 1.28 (0.94–1.74) 0.12 1.19 (1.03–1.38) 0.02
HDREBT; high-dose rate endorectal brachytherapy, CTV; clinical target volume.
Significant results (p values < 0.01) in bold and trends (p value 0.01–0.05) in italics.
* Effect of HDREBT variables on cCR were tested in patients with PR/SD at time of brachytherapy.
A B
No at risk
<10cc 23 14 12 7 3 2
>10cc 10 5 2 2 1 0
No at risk
<20cc 20 14 12 8 3 2
>20cc 12 5 2 1 0 0
C D
p=0.007


























































Fig. 2. Correlation of tumor volume with clinical complete response and sustained partial/complete response A: Correlation of baseline volume with clinical complete
response*. B: Sustained response according to baseline tumor volume. C: Correlation of HDREBT CTV volume with clinical complete response* D: Sustained response
according to HDREBT CTV volume. *Patients with a cCR after EBRT are displayed in gray circles in Figure A and are excluded in Figure C.
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Table 3
Factors associated with toxicity.
q p-Value Explained variance
PROM acute proctitis scale
CTV D98 (Gy/#) 0.43 0.03 18.2
CTV D90 (Gy/#) 0.46 0.02 20.7
CTV D1cc (Gy/#) 0.56 0.003 31.4
CTV D2cc (Gy/#) 0.51 0.007 25.9
CTV D5cc (Gy/#) 0.50 0.03 24.5
CTCAE acute proctitis
Tumor thickness at baseline (mm) 0.44 0.005 19.5
CTV D98 (Gy/#) 0.43 0.01 18.4
CTV D90 (Gy/#) 0.46 0.006 21.0
CTCAE severe late proctitis
CTV D90 (Gy/#) 0.43 0.03 18.5
Endoscopic toxicity at the tumor site
CTV volume (cc) 0.44 0.03 19.4
CTV width (cm) 0.53 0.006 28.1
CTV D1cc (Gy/#) 0.42 0.03 21.0
CTV D2cc (Gy/#) 0.59 0.001 41.7
Volume EQD2 60 Gy (cc) 0.55 0.004 26.2
Volume EQD2 75 Gy (cc) 0.57 0.003 26.6
PROM; patient reported outcome measure, CTV; clinical target volume, Gy/#; Gy
per brachytherapy fraction.
Only factors with a trend or significant correlation are listed. Results of the com-
plete analyses are available online.
Statistics: Spearman’s correlation; significant results (p values < 0.01) in bold and
trends (p value 0.01–0.05) in italics.
180 Predictive factors for response and toxicity after rectal brachytherapythe strongest correlation of q = 0.56 for CTV D1cc. Acute physician
reported toxicity (CTCAE v3) was correlated to tumor thickness at
baseline and HDREBT CTV D90 and D98. Median HDREBT CTV D90
was 6.6 Gy/# (range 4.7–9.3 Gy) for grade 1; 7.8 Gy/# (range 1.8–
9.8 Gy) for grade 2 and 8.7 Gy/# (range 7.2–9.8 Gy) for grade 3
acute proctitis (p = 0.04; see Fig. 3A).
Late proctitis
Severe late proctitis (grade 3 proctitis CTCAE v3) occurred in
10/25 patients who achieved a cCR or cPR. Only HDREBT CTV
D90 showed a correlation (see Table 3 and Fig. 3). Severe late
proctitis occurred in 0/5 (0%) patients with a CTV D90 < 6 Gy/#,
in 5/13 (38%) patients with a CTV D90 between 6 and 8 Gy/#
and in 5/7 (71%) patients with a CTV D90 exceeding 8 Gy/#
(p = 0.02). In multivariable analyses the effect of CTV D90
remained correlated to severe late proctitis after correction for
tumor volume (CTV D90 OR 3.1 (Gy) p = 0.03 and CTV volume
OR 1.3 p = 0.08).
For late rectal bleeding, a trend was observed for use of antico-
agulants: grade2 rectal bleeding occurred in 1/6 patients without
anticoagulants and in 12/19 patients with anticoagulant use
(p = 0.05). Late incontinence was not associated with any of the
clinical or dosimetric parameters (data not shown).
Endoscopic toxicity
Endoscopic toxicity at the contralateral wall showed no corre-
lation with clinical or dosimetric parameters (see Web appendix
A). Endoscopic toxicity at the tumor site was correlated with
HDREBT CTV volume and width, CTV D1cc and D2cc and vol-
umes of 60 and 75 Gy(EQD2a/b3), showing the strongest correla-
tion of q = 0.59 for CTV D2cc. Median CTV D2cc was 10.1 Gy/#
(5.3–12.9) in patients with erythema or scarring, 12.1 Gy/#
(7.7–17.0) in patients with a superficial ulcer and 14.8 Gy/#
(10.1–22.5) in patients with a deep or very deep ulcer (see
Fig. 3D). Deep ulceration occurred in 7/9 (78%) of patients with
a CTV D2cc > 14 Gy/# and in 3/18 (17%) patients with a CTV
D2cc < 14 Gy/# (p = 0.002).Discussion
This sub-analysis of the HERBERT study evaluated factors asso-
ciated with tumor response and toxicity after a combination of
EBRT and a brachytherapy boost in patients with rectal cancer.
The results show that the most important predictor for a clinical
complete response is tumor volume at baseline. Other factors that
were associated with cCR included limited tumor thickness at
baseline, a good response to EBRT and limited circumferential
involvement at time of brachytherapy. Tumor volume, thickness
and circumference at baseline were associated with a sustained
partial/complete response. While we could not demonstrate a rela-
tion between brachytherapy dose and tumor response, a dose–ef-
fect relationship was observed for most toxicity endpoints.
Prescribed dose to the brachytherapy CTV (D90) correlated best
with acute and late physician reported proctitis and high dose
regions in the CTV (D1cc/D2cc) were associated with patient
reported toxicity and endoscopic toxicity at the tumor site.
The current analysis provides unique data on factors associated
with response and toxicity after HDREBT for rectal cancer. While
reports on HDREBT are limited, previous studies on definitive
radiotherapy using contact-X-ray have demonstrated that T-
stage, tumor size, mobility/depth of invasion and early response
to radiotherapy are strong prognostic factors for complete clinical
tumor response [12–16]. Studies evaluating pathologic complete
response after preoperative (chemo)radiotherapy have further
shown a correlation with cT, cN and cM stage, histological subtype
(in favor of adenocarcinoma), differentiation grade, presence of
vascular or lymphatic invasion (LVSI), the addition of neo-
adjuvant chemotherapy, radiotherapy dose escalation and timing
from CRT to surgery [4,17–21].
Factors associated with tumor response in the current study
were tumor volume, thickness, circumferential involvement, cN-
stage and response to EBRT. cT-stage showed no correlation, but
it has long been recognized that tumor volume is a stronger predic-
tor than cT-stage [22,23]. While there was substantial variation in
total cumulative CTV D90, with a median EQD2a/b10 of 72.9 Gy (IQ-
range: 68–80 Gy) we did not observe a dose–response correlation.
This can probably mainly be contributed to the limited number of
35 patients. The effect of dose escalation could also have been
overshadowed by other factors such as tumor volume. Also, the
use of one planning-CT scan for 3 fractions could have resulted
in a different dose coverage at the 2nd and 3rd fraction limiting
the dose–response analyses [9,24]. In addition, while aided by
clips, MRI and endoscopy, soft tissue resolution on CT is poor and
residual uncertainty in delineation may occur [25,26]. A negative
correlation was observed for high dose regions to the brachyther-
apy CTV, which was interpreted, and confirmed by multivariable
analysis, as an indirect effect of tumor volume.
Rectal morbidity after radiotherapy is a well-known problem
and is especially challenging in definitive radiotherapy for rectal
cancer given that the tumor is incorporated in the organ at risk.
Only one study has prospectively evaluated toxicity after chemora-
diation and a HDR boost. Cumulative EQD2 was 66 Gy and
although overall functional outcome was good, rectal bleeding
was present in approximately 80% >1 year after treatment [27].
This study is the first to evaluate prognostic factors for radiation
proctitis in patients with rectal cancer. From previous studies in
patients with prostate and gynecological malignancies we know
that radiation dose and co-morbidity, including diabetes mellitus
and hemorrhoids, have been associated with increased risk of
acute and late rectal toxicity [28]. Additional risk factors for late
rectal morbidity include age, history of abdominal surgery, pres-
ence of cardiovascular disease, use of anticoagulants, smoking
and the presence of acute rectal toxicity [28–33].
Severe late proctitis CTCAE























































Fig. 3. Factors associated with rectal toxicity. HDREBT: high-dose rate endorectal brachytherapy, CTV: clinical target volume. A: Correlation of HDREBT CTV D90 (Gy) with
acute proctitis CTCAE. B: Correlation of HDREBT CTV D90 (Gy) with severe late proctitis CTCAE. C: Correlation of HDREBT CTV volume (cc) with endoscopic toxicity at the
tumor site. D: Correlation of HDREBT CTV D2cc (Gy) with endoscopic toxicity at the tumor site.
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associated with patient and physician reported proctitis and
brachytherapy CTV volume and CTV D1cc and D2cc were corre-
lated with ulceration at the tumor site. No association was
observed for patient comorbidities or dose to the normal rectal
wall. Our study population however existed entirely of elderly/frail
patients with comorbidity who were therefore all at increased risk
of rectal toxicity. Despite the absence of a clear dose–response cor-
relation, it is advisable to limit the dose in the normal mucosa as
much as possible.
Limitations of this study are the small number of patients and
multiple tests performed, making it on the one hand difficult to
distinguish between real effects and random variations, whereas
on the other hand real effects might remain undetected. Also, we
included patients with a partial response in the toxicity analyses
and have to consider the following in the interpretation of the
results. Firstly, proctitis could partly be caused by residual tumor
limiting the correlation with other parameters, and secondly, both
toxicity and tumor regression can result in ulceration. We observed
a correlation for both volume and CTV D2cc with ulceration at the
tumor site, which is likely a combined result of regression in large
tumors and ulceration after high doses to the mucosa.The HDREBT technique has evolved since the HERBERT study
and the current findings have to be validated in future studies
using optimal brachytherapy treatment planning with incorpora-
tion of repeated CT-scanning before every fraction [9,24]. The use
of spacing balloon(s) to improve applicator positioning, together
with optional use of shielding in the central canal, contribute to
decreasing dose to organs at risk [24]. Use of MRI with applicator
in situ, has the advantage of visualization of the residual GTV at
time of brachytherapy, and has been shown to improve the repro-
ducibility of target delineation in other sites [25,26]. MRI would
also allow the use of an adaptive target concept that takes tumor
regression during treatment into account and can further direct
dose optimization for areas at risk of macroscopic residual tumor
and at risk for microscopic disease. Consensus on target definition
and dose reporting are needed to further improve the understand-
ing of dose–effect relationships for HDREBT from an international
perspective.
The findings of the current study can be useful in selection of
patients for definitive radiotherapy. It seems that patients with a
baseline tumor volume <20 cc and at least a partial response to
EBRT are good candidates for a brachytherapy boost. Use of antico-
agulants increases the risk of late rectal blood loss and this should
182 Predictive factors for response and toxicity after rectal brachytherapybe considered when counseling patients for this treatment. As pre-
viously reported, the recommended brachytherapy boost dose
after 13x3Gy EBRT was determined to be 7 Gy per fraction [6].
Based on the current analyses we advise to aim for a maximum
CTV/rectal wall D2cc of 200% (14 Gy/#) to limit the risk of deep
ulceration. While some of the patients that were treated with
7 Gy per fraction did experience severe late proctitis, we expect
that with improved patient selection, technique and the suggested
additional constraint we will observe less severe toxicity. Further
research on the added value and risks of a HDREBT boost in elderly
patients with limited treatment options is necessary. A proposed
follow-up study for medically inoperable rectal cancer patients
(HERBERT II) will randomize between EBRT alone and EBRT fol-
lowed by a HDREBT boost using these treatment planning aims.
Disclaimers




Appendix A. Supplementary data
Supplementary data to this article can be found online at
https://doi.org/10.1016/j.radonc.2019.01.034.
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